RadNet, Inc. Announces That It Has Received FDA Clearances for Its DeepHeatlh Saige-DX Mammography and Quantib® Prostate 2.0 MRI Artificial Intelligence ("Ai") Algorithms
May 16, 2022 at 06:00 am EDT
Share
RadNet, Inc. announced that it has received FDA clearances for its DeepHeatlh Saige-DX mammography and Quantib® Prostate 2.0 MRI artificial intelligence ("AI") algorithms. Saige-Dx, a more advanced successor to FDA approved Saige-Q worklist triage software, is a cancer detection tool that enables radiologists to more effectively detect the presence or absence of breast cancer with the use of artificial intelligence. DeepHealth's powerful new AI technology automatically identifies suspicious lesions in mammograms and assigns a suspicion level to each finding and to the entire case. It helps detect and diagnose breast cancer earlier while reducing unnecessary recalls.
Quantib® Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station. The solution comes with a suite of tools to improve reporting quality and speed, including AI-based segmentations and volumetry, PSA density calculation, precise registration and movement correction, one-click segmentation of lesion candidates, PI-RADS scoring support, and standardized reporting to facilitate easy and comprehensive communication of results. FDA 510k special clearance has been given for a major upgrade to the solution (from release 1.3) that now includes fully automatic prostate zone segmentation (in addition to prostate gland segmentation) and automated initiation of localization of lesions on the PI-RADS sector map.
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States. It has a network of 366 owned and/or operated outpatient imaging centers. The Companyâs Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The Companyâs Artificial Intelligence (AI) segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate and pulmonary diagnostics. The Company, through its joint ventured Arizona Diagnostic Radiology Group, LLC, owns seven outpatient imaging centers.
RadNet, Inc. Announces That It Has Received FDA Clearances for Its DeepHeatlh Saige-DX™ Mammography and Quantib® Prostate 2.0 MRI Artificial Intelligence ("Ai") Algorithms